8-KItem 8.01 · Other Events
Bio-Techne supplements Merck merger proxy after shareholder lawsuit
Filed with the SEC on · Summarized by InvestorsBot
Bio-Techne disclosed a shareholder lawsuit filed September 9, 2026, and multiple demand letters alleging that its proxy statement omitted or misrepresented material information ahead of the September 23 shareholder vote on Merck KGaA’s proposed acquisition. The company denies the allegations but voluntarily added disclosures, including Goldman Sachs’ updated valuation ranges of $58 to $72 per share and $49 to $67 per share, while noting that the outcome and potential losses from the legal claims cannot be predicted.